Friedreich's Ataxia: Disease mechanisms, antioxidant and Coenzyme Q 10 therapy

BioFactors

Volumn 18, Issue 1-4, 2003, Pages 163-171

  Cooper, J M ^a   Schapira, A H V ^a,b  

^a ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCYSTEINE; ALPHA TOCOPHEROL; ANTIOXIDANT; IDEBENONE; IRON; IRON SULFUR PROTEIN; SELENIUM; UBIDECARENONE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIOXIDANT ACTIVITY; ATAXIA; COMBINATION CHEMOTHERAPY; CONFERENCE PAPER; CONTROLLED STUDY; DISEASE COURSE; ENZYME THERAPY; FRIEDREICH ATAXIA; GENETIC DISORDER; HEART HYPERTROPHY; HEART MUSCLE; HUMAN; IRON TRANSPORT; MITOCHONDRIAL RESPIRATION; MOUSE; NONHUMAN; OXIDATIVE STRESS; PATHOGENESIS; PREDICTION; PRIORITY JOURNAL; PROTEIN DEFICIENCY; SKELETAL MUSCLE; SYMPTOMATOLOGY; SYNTHESIS; VITAMIN DEFICIENCY; VITAMIN METABOLISM;

ANIMALIA; ATAXIA;

EID: 0346158441     PISSN: 09516433     EISSN: None     Source Type: Journal    
DOI: 10.1002/biof.5520180219     Document Type: Conference Paper

References (64)

1. J. Adamec, F. Rusnak, W.F. Owen, S. Naylor, L.M. Benson, A.M. Gacy and G. Isaya, Iron-dependent self-assembly of recombinant yeast frataxin: implications for Friedreich's ataxia, Ann J Hum Genet 67 (2000), 549-562.
2. M. Babcock, D. de Silva, R. Oaks, S. Davis-Kaplan, S. Jiralerspong, L. Montermini et al., Regulation of mitochondrial iron accumulation by Yfhlp, a putative homolog of frataxin, Science 276 (1997), 1709-1712.
3. R.E. Beyer, An analysis of the role of coenzyme Q in free radical generation and as an antioxidant, Biochem Cell Biol 70 (1992), 390-403.
4. S.I. Bidichandani, T. Ashizawa and P.I. Patel, The GAA triplet-repeat expansion Friedreich's ataxia interferes with transcription and may be associated with an unusual DNA structure, Am J Hum Genet 62 (1998), 111-121.
5. R.M. Bostick, J.D. Potter, D.R. McKenzie, T.A. Sellers, L.H. Kushi, K.A. Steinmetz et al., Reduced risk of colon cancer with high intake of vitamin E: the Iowa Women's Health Study, Cancer Res 53 (1993), 4230-4237.
6. J.L. Bradley, J.C. Blake, S. Chamberlain, P.K. Thomas, J.M. Cooper and A.H.V. Schapira, Clinical, biochemical and molecular genetic correlations in Friedreich's ataxia, Hum Mol Genet 9 (2000), 275-282.
7. M. Bunse, N. Bit-Avragim, A. Riefflin, A. Perrot, O. Schmidt, F.R. Kreuz et al., Cardiac energetics correlates to myocardial hypertrophy in Friedreich's Ataxia, Annn Neurol 53 (2003), 121-123.
8. J.L. Buttriss and A.T. Diplock, The alpha-tocopherol and phospholipid fatty acid content of rat liver subcellular membranes in vitamin E and selenium deficiency, Biochim Biophys Acta 963 (1988), 61-69.
9. V. Campuzano, L. Montermini, M.D. Molto, L. Pianese, M. Cossee, F. Cavalcanti et al., Friedreich's ataxia: autosomal recessive disease caused by an intronic GAA triplet repeat expansion, Science 271 (1996), 1423-1427.
10. V. Campuzano, L. Montermini, Y. Lutz, L. Cova, C. Hindelang, S. Jiralerspong et al., Frataxin is reduced in Friedreich's ataxia patients and is associated with mitochondrial membranes, Hum Mol Genet 6 (1997), 1771-1780.
11. P. Cavadini, H.A. O'Neill, O. Benada and G. Isaya, Assembly and iron-binding properties of human frataxin, the protein deficient in Friedreich ataxia, Hum Mol Genet 11 (2002), 217-227.
12. L. Cavalier, K. Ouahchi, H.J. Kayden, S. Di Donato, L. Reutenauer, J.L. Mandel et al., Ataxia with isolated vitamin E deficiency: heterogeneity of mutations and phenotypic variability in a large number of families, Am J Hum Genet 62 (1998), 301-310.
13. K. Chantrel-Groussard, V. Geromel, H. Puccio, M. Koenig, A. Munnich, A. Rotig and P. Rustin, Disabled early recruitment of antioxidant defenses in Friedreich's ataxia, Hum Mol Genet 10 (2001), 2061-2067.
14. M.B. Delatycki, J. Camakaris, H. Brooks, T. Evans-Whipp, D.R. Thorburn, R. Williamson et al., Direct evidence that mitochondrial iron accumulation occurs in Friedreich's ataxia, Ann Neurol 45 (1999), 673-675.
15. S. Dhe-Paganon, R. Shigesta, Y.-I. Chi, M. Ristow and S.E. Shoelson, Crystal structure of human frataxin, J Biol Chem 275 (2000), 30753-30756.
16. A. Durr, M. Cossee, Y. Agid, V. Campuzano, C. Mignard, C. Penet et al., Clinical and genetic abnormalities in patients with Friedreich's ataxia, N Engl J Med 335 (1996), 1169-1175.
17. M. Emond, G. Lepage, M. Vanasse and M. Pandolfo, Increased levels of plasma malondialdehyde in Friedreich's ataxia, Neurology 55 (2000), 1752-1753.
18. L. Ernster and G. Dallner, Biochemical, physiological and medical aspects of ubiquinone function, Biochim Biophys Acta 1271 (1995), 195-204.
19. A. Filla, G. De Michele, F. Cavalcanti, L. Pianese, A. Monticelli, G. Campanella et al., The relationship between trinucleotide (GAA) repeat length and clinical features in Friedreich ataxia, Am J Hum Genet 59 (1996), 554-560.
20. 10 with 3 months withdrawal period, Mol Aspects Med Suppl 15 (1996), s281-285.
21. F. Foury and O. Cazzalini, Deletion of the yeast homologue of the human gene associated with Friedreich's ataxia elicits iron accumulation in mitochondria, FEBS Lett 411 (1997), 373-377.
22. F. Foury, Low iron concentration and aconitase deficiency in a yeast frataxin homologue deficient strain, FEBS Lett 456 (1999), 281-284.
23. M.J. Fryer, Rationale for clinical trials of selenium as an antioxidant for the treatment of the cardiomyopathy of Friedreich's ataxia, Med. Hypotheses 58 (2002), 127-132.
24. S. Gabsi, N. Gouider-Khouja, S. Belal, M. Fki, M. Kefi, I. Turki et al., Effect of vitamin E supplementation in patients with ataxia with vitamin E deficiency, Eur J Neurol 8 (2001), 477-481.
25. H. Gutzmann and D. Hadler, Sustained efficacy and safety of idebenone in the treatment of Alzheimer's disease: update on a 2-year double-blind multicentre study, J Neural Transm Suppl 54 (1998), 301-310.
26. A.E. Harding, Friedreich's ataxia: a clinical and genetic study of 90 families with an analysis of early diagnosis criteria and intrafamilial clustering of clinical features, Brain 104 (1981), 589-620.
27. E. Hasegawa, K. Takeshige, T. Oishi, Y. Murai and S. Minakami, 1-Methyl-4-phenylpyridinium (MPP+) induces NADH-dependent superoxide formation and enhances NADH-dependent lipid peroxidation in bovine heart submitochondrial particles, Biochem Biophys Res Commun 170 (1990), 1049-1055.
28. A. Hausalden and I. Fridovich, Superoxide and peroxynitrite inactivate aconitase, but nitric oxide does not, J Biol Chem 269 (1994), 29405-29408.
29. A.O. Hausse, Y. Aggoun, D. Bonnet, D. Sidi, A. Munnich, A. Rotig et al., Iebenone and reduced cardiac hypertrophy in Friedreich's ataxia, Heart 87 (2002), 346-349.
30. M.A. Huynen, B. Snel, P. Bork and T.J. Gibson, The phylogenetic distribution of frataxin indicates a role in iron-sulphur cluster protein assembly, Hum Mol Genet 10 (2001), 2463-2468.
31. J.S. Ingwall, M.F. Kramer, M.A. Fifer, B.H. Lorell, R. Shermin, W. Grossman et al., The creatine kinase system in normal and diseased human myocardium, N Engl J Med 313 (1985), 1050-1054.
32. S. Jiralerspong, B. Ge, T.J. Hudson and M. Pandolfo, Manganese superoxide dismutase induction by iron is impaired in Friedreich's ataxia cells, FEBS Lett 509 (2001), 101-105.
33. G.J. Kemp, D.J. Taylor, C.H. Thompson, L.J. Hands, B. Rajagopalan, P. Styles et al., Quantitative analysis by 31P magnetic resonance spectroscopy of abnormal mitochondrial oxidation in skeletal muscle during recovery from exercise, NMR Biomed 6 (1993), 302-310.
34. G. Kispal, P. Csere, C. Prohl, and R. Lill, The mitochondrial proteins Atm1p and Nfs1p are essential for biogenesis of cytosolic Fe/S proteins, EMBO J 18 (1999), 3981-3989.
35. H. Koutnikova, V. Campuzano, F. Foury, P. Dollé, O. Cazzalini and M. Koenig, Studies of human, mouse and yeast homologues indicate a mitochondrial function for frataxin, Nature Genetics 16 (1997), 345-351.
36. J.B. Lamarche, D. Shapcott, M. Cote and B. Lemieux, Cardiac iron deposits in Friedreich's ataxia, in: Handbook of cerebellar diseases, R. Lechtenberg, ed., Marcel Dekker, New York, 1993, pp. 453-456.
37. 10 deficiency, Neurology 60 (2003), 1206-1208.
38. J. Li, M. Kogan, S.A. Knight, D. Pain and A. Dancis, Yeast mitochondrial protein, Nfs1p, coordinately regulates iron-sulfur cluster proteins, cellular iron uptake, and iron distribution, J Biol Chem 274 (1999), 33025-33034.
39. R. Lill, K. Diekert, A. Kaut, H. Lange, W. Pelzer, C. Prohl et al., The essential role of mitochondria in the biogenesis of cellular iron-sulfur proteins, Biol Chem 380 (1999), 1157-1166.
40. R. Lodi, J.M. Cooper, J.L. Bradley, D. Manners, P. Styles, D.J. Taylor et al., Deficit of in vivo mitochondrial ATP production in patients with Friedreich's ataxia, Proc Natl Acad Sci USA 96 (1999), 11492-11495.
41. R. Lodi, B. Rajagopalan, A.M. Blamire, J.M. Cooper, C.H. Davies, J.L. Bradley et al., Cardiac energetics are abnormal in Friedreich's ataxia patients in the absence of cardiac dysfunction and hypertrophy. An in vivo 31P magnetic resonance spectroscopy study is abnormal, Cardiovascular Res 52 (2001), 111-119.
42. R. Lodi, B. Rajagopalan, P.E. Hart, A.M. Blamire, J.G. Crilley, J.L. Bradley et al., Antioxidant treatment improves in vivo cardiac and skeletal muscle bioenergetics in patients with Friedreich's Ataxia, Ann Neurol 49 (2001), 590-596.
43. 10 administration increases brain mitochondrial concentrations and exerts neuroprotective effects, Proc Natl Acad Sci USA 95 (1998), 8892-8897.
44. S. Melov, P. Coskun, M. Patel, R. Tuinstra, B. Cottrell, A.S. Jun et al., Mitochondrial disease in superoxide dismutase 2 mutant mice, Proc Natl Acad Sci USA 96 (1999), 846-851.
45. A. Mordente, G.E. Martorana, G. Minotti and B. Giardina, Antioxidant properties of 2,3-dimethoxy-5-methyl-6-(10-hydroxydecyl)-1,4-benzoquinone (idebenone), Chem Res Toxicol 11 (1998), 54-63.
46. Y. Nagai, K. Yoshida, S. Narumi, S. Tanayama and A. Nagaoka, Brain distribution of idebenone and its effect on local cerebral glucose utilization in rats, Arch Gerontol Geriatr 8 (1989), 257-272.
47. F. Piemonte, A. Pastore, G. Tozzi, D. Tagliacozzi, F.M. Santorelli, R. Carrozzo et al., Glutathione in blood of patients with Friedreich's ataxia, Eur J Clin Invest 31 (2001), 1007-1011.
48. M.A. Pook, S.A.H. Al-Mahdawi, N.H. Thomas, R. Appleton, A. Norman, R. Mountford et al., Identification of three novel frameshift mutations in patients with Friedreich's ataxia, J Med Gen 37 (2000), E38.
49. H. Puccio, D. Simon, M. Cessée, P. Criqui-Filipe, F. Tiziano, J. Melki et al., Mouse models for Friedreich's ataxia exhibit cardiomyopathy, sensory nerve defect and Fe-S enzyme deficiency followed by intramitochondrial iron deposits, Nature Gen 27 (2001), 181-186.
50. N.G. Ranen, C.E. Peyser, J.T. Coyle, F.W. Bylsma, M. Sherr, L. Day et al., A controlled trial of idebenone in Huntington's disease, Mov Disord 11 (1996), 549-554.
51. S. Reahal and J. Wrigglesworth, Tissue concentrations of coenzyme Q10 in the rat following its oral and intraperitoneal administration, Drug Metab Dispos 20 (1992), 423-427.
52. D.R. Richardson, C. Mouralian, P. Ponka and E. Becker, Development of potential iron chelators for the treatment of Friedreich's ataxia: ligands that mobilise mitochondrial iron, Biochim et Biophys Acta 1536 (2001), 133-140.
53. A. Rotig, P. de Lonlay, D. Chretien, F. Foury, M. Koenig, D. Sidi et al., Aconitase and mitochondrial iron-sulphur protein deficiency in Friedreich's ataxia, Nature Genetics 17 (1997), 215-217.
54. L. Schols, M. Vorgerd, M. Schillings, G. Skipka and J. Zange, Idebenone in patients with Friedreich ataxia, Neurosci Lett 306 (2001), 169-172.
55. J.B. Schultz, T. Dehmer, L. Schöls, H. Mende, C. Hardt, M. Vorgerd et al., Oxidative stress in patients with Friedreich's ataxia, Neurology 55 (2000), 1719-1721.
56. I. Shoulson, DATATOP: a decade of neuroprotective inquiry. Parkinson Study Group. Deprenyl and tocopherol antioxidative therapy of Parkinsonism, Ann Neurol 44 (1998), S160-166.
57. R.A. Smith, C.M. Porteous, C.V. Coulter and M.P. Murphy, Selective targeting of an antioxidant to mitochondria, Eur J Biochem 263 (1999), 709-716.
58. N.G. Stephens, A. Parsons, P.M. Schofield, F. Kelly, K. Cheeseman and M.J. Mitchinson, Randomised controlled trial of vitamin E in patients with coronary disease: Cambridge Heart Antioxidant Study (CHAOS), Lancet 347 (1996), 781-786.
59. S.J. Tabrizi, J. Workman, P.E. Hart, L. Mangiarini, A. Mahal, G. Bates et al., Mitochondrial dysfunction and free radical damage in the Huntington R6/ 2 transgenic mouse, Ann Neurol 47 (2000), 80-86.
60. P.K. Thomas, J.M. Cooper, R.H. King, J.M. Workman, A.H. Schapira, M.A. Goss-Sampson et al., Myopathy in vitamin E deficient rats: muscle fibre necrosis associated with disturbances of mitochondrial function, J Anat 183 (1993), 451-461.
61. M. Vorgerd, L. Schols, C. Hardt, M. Ristow, J.T. Epplen and J. Zange, Mitochondrial impairment of human muscle in Friedreich's Ataxia in vivo, Neuromuscul Disord 10 (2000), 430-435.
62. R.B. Wilson, D.R. Lynch and K.H. Fischbeck, Normal serum iron and ferritin concentrations in patients with Friedreich's ataxia, Ann Neurol 44 (1998), 132-134.
63. A. Wong, J. Yang, P. Cavadini, C. Gellera, B. Lonnerdal, F. Taroni et al., The Friedreich's ataxia mutation confers cellular sensitivity to oxidant stress which is rescued by chelators of iron and calcium and inhibitors of apoptosis, Hum Mol Genet 8 (1999), 425-430.
64. Y. Zhang, F. Aberg, E.L. Appelkvist, G. Dallner and L. Ernster, Uptake of dietary coenzyme Q supplement is limited in rats, J Nutr 125 (1995), 446-453.